Paul L. Berns, President and CEO at Anacor Pharmaceuticals, Inc. (ANAC), sold 20,000 shares at $140.64 ($2.8M) on 2015-09-15, disclosed to the SEC on 2015-09-17.
Scheduled sale ($2.8M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $139.03 | 1,992 | $277K | 9.9% |
| 2 | $139.83 | 16,209 | $2.3M | 81.0% |
| 3 | $140.64 | 1,799 | $253K | 9.0% |
| Total | $139.82 avg | 20,000 | $2.8M | 100% |
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |